CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $102,536 | +135.9% | 3,448 | +43.0% | 0.00% | – |
| Q2 2023 | $43,461 | +441.3% | 2,412 | +382.4% | 0.00% | – |
| Q1 2023 | $8,029 | +100.7% | 500 | +96.1% | 0.00% | – |
| Q4 2022 | $4,000 | -20.0% | 255 | 0.0% | 0.00% | – |
| Q3 2022 | $5,000 | +25.0% | 255 | +10.9% | 0.00% | – |
| Q2 2022 | $4,000 | -84.6% | 230 | -80.0% | 0.00% | – |
| Q1 2022 | $26,000 | -40.9% | 1,150 | -24.6% | 0.00% | – |
| Q4 2021 | $44,000 | +41.9% | 1,525 | +5.2% | 0.00% | – |
| Q3 2021 | $31,000 | +14.8% | 1,450 | 0.0% | 0.00% | – |
| Q2 2021 | $27,000 | +285.7% | 1,450 | +222.2% | 0.00% | – |
| Q1 2021 | $7,000 | – | 450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |